PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Pulmonary fibrosis is a progressive life-threatening disease for which no effective therapy exists. Myofibroblasts are one of the key effector cells in pulmonary fibrosis and are the primary source of extracellular matrix production. Drugs that inhibit the differentiation of fibroblasts to myofibroblasts have potential as antifibrotic therapies. Peroxisome proliferator-activated receptor (PPAR)-γ is a transcription factor that upon ligation with PPARγ agonists activates target genes containing PPAR response elements. PPARγ agonists have anti-inflammatory activities and may have potential as antifibrotic agents. In this study, we examined the abilities of PPARγ agonists to block two of the most important profibrotic activities of TGF-β on pulmonary fibroblasts: myofibroblast differentiation and production of excess collagen. Both natural (15d-PGJ 2) and synthetic (ciglitazone and rosiglitazone) PPARγ agonists inhibited TGF-β-driven myofibroblast differentiation, as determined by α-smooth muscle actin-specific immunocytochemistry and Western blot analysis. PPARγ agonists also potently attenuated TGF-β-driven type I collagen protein production. A dominant-negative PPARγ partially reversed the inhibition of myofibroblast differentiation by 15d-PGJ 2 and rosiglitazone, but the irreversible PPARγ antagonist GW-9662 did not, suggesting that the antifibrotic effects of the PPARγ agonists are mediated through both PPARγ-dependent and independent mechanisms. Thus PPARγ agonists have novel and potent antifibrotic effects in human lung fibroblasts and may have potential for therapy of fibrotic diseases in the lung and other tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, N. S. A., Di Paola, R., Ialenti, A., Genovese, T., Chatterjee, P. K., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.056 · Cited by 214
RetractedMosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“This complex recognizes PPAR response elements (PPRE) in promoters on target genes resulting in the regulation of gene transcription (3, 5, 36).”
BackgroundRegulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Cited by
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Takacs, M. L., & Abbott, B. D. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl135 · Cited by 396
“The agonists and antagonists selected for this study were chosen for their selective activation or antagonism of mouse and human PPARa, b/d, c isoforms (Berger et al., 1999; Bility et al., 2004; Burgess et al., 2005; Kehrer et al., 2001; Lehmann et al., 1995; Maloney and Waxman, 1999; Peraza et al., 2006; Shipley et a…”
BackgroundThe Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar Macrophages
Yu, X., Buttgereit, A., Lelios, I., Utz, S. G., Cansever, D., Becher, B., & Greter, M. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.007 · Cited by 352
Cardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
Andrews, T. S., Atif, J., Liu, J. C., Perciani, C. T., Ma, X., Thoeni, C., Slyper, M., Eraslan, G., Segerstolpe, A., Manuel, J., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1854 · Cited by 307
An essential role for fibronectin extra type III domain A in pulmonary fibrosis
Muro, A. F., Moretti, F. A., Moore, B. B., Yan, M., Atrasz, R. G., Wilke, C. A., Flaherty, K. R., Martinez, F. J., Tsui, J. L., Sheppard, D., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1291oc · Cited by 297
“Physiologic (or pathologic) factors that induce EDA cFN production are poorly defined, although the molecular mechanisms regulating alternative EDA exon splicing have been well described (8, 9). Interestingly, one known factor that promotes EDA inclusion into FN is transforming growth factor (TGF)-b1, a cytokine impli…”
BackgroundMetformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis
Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., Weiss, A., Wilhelm, J., Zhang, J.-S., Kwapiszewska, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10839-0 · Cited by 293
Cell traction force and measurement methods
Wang, J. H.-C., & Lin, J.-S. (2007) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-006-0068-4 · Cited by 264
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B., Phipps, R. P., & Sime, P. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015909 · Cited by 189
“However, we [27,28,33] and others [32], have shown that PPAR-c ligands also have effects that are independent of PPAR-c activity.”
BackgroundInfluentialSelf-citationThe nox4 inhibitor gkt137831 attenuates hypoxia-induced pulmonary vascular cell proliferation
Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0418oc · Cited by 146
Yoon, Y.-S., Kim, S.-Y., Kim, M.-J., Lim, J.-H., Cho, M.-S., & Kang, J. L. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.130 · Cited by 145
Ushakumary, M. G., Riccetti, M., & Perl, A.-K. T. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0526 · Cited by 100
PPAR-γ Activation As an Anti-inflammatory Therapy for Respiratory Virus Infections
Bassaganya-Riera, J., Song, R., Roberts, P. C., & Hontecillas, R. (2010) · Viral Immunology · doi:10.1089/vim.2010.0016 · Cited by 83
Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet
Xu, J., Mora, A. L., LaVoy, J., Brigham, K. L., & Rojas, M. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00006.2006 · Cited by 63
Chang, H. J., Lee, J. H., Hwang, K. J., Kim, M. R., Chang, K. H., Park, D. W., & Min, C. K. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.09.010 · Cited by 33
Metadata
- Authors
- Burgess, H. A., Daugherty, L. E., Thatcher, T. H., Lakatos, H. F., Ray, D. M., Redonnet, M., Phipps, R. P., & Sime, P. J.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2005-06
- Volume
- 288
- Issue
- 6
- Pages
- L1146-L1153
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2107356121
- Cited by
- 317
- References
- 38
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.